[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344363-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344363-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","germline-pathogenic-variants-identified-in-patients-with-genitourinary-malignancies-undergoing-universal-testing-a-multisite-single-institution-prospective-study","Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing - A Multisite Single-Institution Prospective Study","","Universal germline genetic testing was offered to patients with new or active genitourinary malignancies across Mayo Clinic sites from April 2018 to March 2020. The study assessed the prevalence of pathogenic germline variants in hereditary cancer genes and quantified PGVs that would have been missed under NCCN GU malignancy guidelines. Over 1 in 8 patients carried a PGV, and most high-penetrance findings led to clinically actionable management changes, supporting broad-based testing to improve risk assessment and precision care.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/germline-pathogenic-variants-identified-in-patients-with-genitourinary-malignancies-undergoing-universal-testing-a-multisite-single-institution-prospective-study/344363/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/germline-pathogenic-variants-identified-in-patients-with-genitourinary-malignancies-undergoing-universal-testing-a-multisite-single-institution-prospective-study/344363.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-22","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of the universal testing approach in this study?","Question",{"text":63,"@type":64},"To determine how common pathogenic germline variants were in hereditary cancer genes among genitourinary malignancy patients and to estimate how many PGVs NCCN guidelines would have missed.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the key findings regarding PGV prevalence and clinical actionability?",{"text":68,"@type":64},"More than 1 in 8 patients carried a PGV, and 67% of patients with high-penetrance PGVs had clinically actionable changes based on results.",{"name":70,"@type":61,"acceptedAnswer":71},"What limitations did the study report?",{"text":72,"@type":64},"Relatively short follow-up and a small sample size, along with limits on generalizability because all patients were receiving care at a tertiary center.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344363,1790386751,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","[www.auajournals.org/journal/juro](www.auajournals.org/journal/juro)  \nNew Technology, Digital Health, and Artiﬁcial Intelligence  \nJU Insight  \nGermline Pathogenic Variants Identiﬁed in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite  \nSingle-Institution Prospective Study  \nMouneeb M. Choudry, Adri M. Durant , Victoria S. Edmonds, et al.  \nCorrespondence: Adri Durant ([durant.adri@mayo.edu](durant.adri@mayo.edu)).  \nFull-length article available at [https://doi.org/10.1097/JU.0000000000004089](https://doi.org/10.1097/JU.0000000000004089).  \nStudy Need and Importance: Identifying pathogenic germline variants (PGVs) in genitourinary (GU) cancer patients can have important implications for treatment decisions, cancer screening, and germline testing for close relatives. This study aimed to investigate the prevalence of PGVs in hereditary cancer genes utilizing a universal testing approach and to determine the rate of PGVs that would have been missed based on National Comprehensive Cancer Network guidelines in GU malignancies.  \nWhat We Found: A multisite, single-institution prospective germline genetic test (GGT) was universally offered to patients with new or active diagnoses of GU malignancies. More than 1 in 8 patients with GU malignancies were found to carry a PGV (Figure), with 67% of patients with high-penetrance PGVs undergoing clinically actionable changes. PGV-positive patients who would not have received testing based on National Comprehensive Cancer Network guidelines were identiﬁed in 28 (57%) prostate, 15 (100%) bladder, and 14 (78%) renal cancer patients. Limitations: The limitations of our study include the relatively short follow-up period and small sample size. In addition, there are limitations to the generalizability of the study, given that all patients were seeking care at a tertiary care center. Interpretation for Patient Care: These ﬁndings support universal GGT for GU malignancies and underscore its potential to enhance risk assessment and guide precision interventions in urologic oncology. Our study contributes to the expanding body of evidence supporting the importance of considering PGV in traditional high-risk scenarios and across a broader spectrum of patients affected by GU cancers. As novel therapeutic strategies emerge that target speciﬁc genetic vulnerabilities, our study reinforces the necessity of broadbased GGT to identify these susceptibilities and optimize treatment approaches in urologic oncology. THE JOURNAL OF UROLOGY®  \n􀀁 2024 The Author(s) . Published on behalf of the  \nAmerican Urological Association, Education and Research, Inc.  \n[590](590 j www.auajournals.org/jurology)[ j](590 j www.auajournals.org/jurology)[ www.auajournals.org/jurology](590 j www.auajournals.org/jurology)  \nFigure. Distribution of germline testing results for prostate patients (A), renal patients (B), and bladder patients (C) . VUS indicates variants of uncertain signiﬁcance.  \n[https://doi.org/10.1097/JU.0000000000004089](https://doi.org/10.1097/JU.0000000000004089)[ ](https://doi.org/10.1097/JU.0000000000004089)Vol. 212, 590-599, October 2024 Printed in U.S.A.  \n[www.auajournals.org/journal/juro](www.auajournals.org/journal/juro)  \nGermline Pathogenic Variants Identiﬁed in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study  \nMouneeb M. Choudry, 1 * Adri M. Durant , 1 * Victoria S. Edmonds, 1 Christopher J. Warren, 1 Katie L. Kunze,2 Michael A. Golafshar,2 Sarah M. Nielsen,3 Edward D. Esplin,3 Jack R. Andrews, 1 N. Jewel Samadder,4,5,6 and Mark D. Tyson 1  \n1Department of Urology, Mayo Clinic, Phoenix, Arizona  \n2Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona 3Invitae Corporation, San Francisco, California  \n4Department of Clinical Genomics, Mayo Clinic, Phoenix, Arizona 5Center for Individualized Medicine, Mayo Clinic, Phoenix, Arizona  \n6Division of Gastroenterology and Hepatolog","cbCaimI6xxdzDHrF","https://ap.wps.com/l/cbCaimI6xxdzDHrF","pdf",533624,"English","# Study Need and Importance\n# What We Found\n# Materials and Methods\n## Next-Generation Sequencing Panel\n# Limitations\n# Interpretation for Patient Care","[{\"question\":\"What was the purpose of the universal testing approach in this study?\",\"answer\":\"To determine how common pathogenic germline variants were in hereditary cancer genes among genitourinary malignancy patients and to estimate how many PGVs NCCN guidelines would have missed.\"},{\"question\":\"What were the key findings regarding PGV prevalence and clinical actionability?\",\"answer\":\"More than 1 in 8 patients carried a PGV, and 67% of patients with high-penetrance PGVs had clinically actionable changes based on results.\"},{\"question\":\"What limitations did the study report?\",\"answer\":\"Relatively short follow-up and a small sample size, along with limits on generalizability because all patients were receiving care at a tertiary center.\"}]","Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing - A Multisite Single-Institution Prospective Study | PDF",1790053485,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3ebf4c001ab02698cc375642cd0ecab.webp",983,1315,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b577ee93d29f45faedea48093429876d.webp",982,1314,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc8807900779e470170c471298f77ed1.webp",981,1312,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67dd3ed733d2d3d50b233ee149e8b421.webp",980,1311]